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1105 AZ Amsterdam, The NetherlandsSummary and non-alcoholic steatohepatitis-associated liver cirrhosis. LiverMicroRNAs (miRNAs) are evolutionary conserved small non-
coding RNAs that regulate gene expression by mediating post-
transcriptional silencing of target genes. Since miRNAs are
involved in ﬁne-tuning of physiological responses, they have
become of interest for diagnosis and therapy of a number of dis-
eases. Moreover, the role of dysregulated miRNAs in maintaining
the malignant phenotype has profound implications for cancer
therapy. We will review the best deﬁned cellular miRNAs and
changes in their expression proﬁle in hepatocellular carcinoma
(HCC). Cellular miRNAs can also be released into the circulation,
and these miRNAs are detected in most body ﬂuids. Circulating
miRNAs are associated with HCC and are possible biomarkers.
Finally, by affecting several clinically relevant targets, artiﬁcially
increasing or decreasing the expression level of a given miRNA
offers fascinating therapeutic perspectives. We will therefore
highlight recent developments in miRNA-based gene therapy
with a focus on their therapeutic potential for HCC.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is the major primary liver can-
cer, which is the ﬁfth most common cause of cancer worldwide
[1], with about 750,000 patients globally reported each year
(International Agency for Research on Cancer, IARC). An esti-
mated 80–90% of all HCCs arise from the cirrhotic liver. Major risk
factors are chronic viral hepatitis B (HBV) or C (HCV), which
account for 80–90% of all HCCs worldwide [2], and alcoholicJournal of Hepatology 20
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carboxyprothrombin.cancer is the third cancer-related cause of death, with an annual
mortality of about 700,000 persons globally. Low survival is
attributed to late diagnosis, resistance to treatment, tumor recur-
rence, and metastasis, hence stressing the need for novel diagnos-
tics and therapeutics. Speciﬁc miRNAs have been shown to be
involved in various biological processes, including development,
cellular proliferation, apoptosis, and oncogenesis [3]. The ﬁnding
that individual miRNAs may target several hundred genes, and
that a large percentage of mRNAs may be subject to regulation
by miRNAs, further underscores the emerging importance of miR-
NA-mediated regulation [4,5]. Here, we review miRNA biogenesis
and its alterations as well as miRNA polymorphisms linked to
HCC, miRNA detection methods, the association of cellular and
circulating miRNAs expression patterns with HCC, their predicted
target genes, and discuss the diagnostic and therapeutic potential
of some miRNAs.
Key Points 1
• miRNAs are ~22-nt long RNAs implicated in post-
transcriptional regulation of various biological processes 
including development, cellular proliferation, apoptosis, 
and oncogenesis
• miRNA biogenesis involves multiple steps requiring 
nucleases Drosha and Dicer to process the initial 1-4 kb 
transcript called pri-miRNA, with intermediate pre-miRNA 
of ~70-nt long, into the mature miRNA ~22-nt long RNAmiRNA expression proﬁles associated with HCC
miRNA biogenesis and mechanism of action
miRNAs are endogenous 22-nt long single stranded RNAs. There
are currently 1492 human miRNA sequences registered in the
miRBase database (http://www.mirbase.org). miRNAs are non-
coding but are implicated in post-transcriptional regulation of
genes involved in fundamental cell processes and in diseases
[3]. The miRNA gene is usually transcribed by RNA polymerase
II in the nucleus into a primary transcript called pri-miRNA
(Fig. 1A) of approximately 1–4 kb [6]. These transcripts can be12 vol. 56 j 1371–1383
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either monocistronic – a single miRNA gene behind a promoter –
or polycistronic – expressed from one transcript as a cluster con-
taining several miRNA gene products e.g. the miR-1792 miRNA
polycistron [7]. Depending on their genome position, globally
about 50% of all miRNA genes are intragenic, the so-called mir-
trons – likely to be regulated through their host gene – but they
can also be located in intergenic regions i.e. likely to be indepen-
dent transcriptional units [8]. The pri-miRNA is then cleaved by
the microprocessor complex which consists of the nuclease Dro-
sha and the double-stranded RNA-binding protein DiGeorge syn-
drome critical region gene 8 (DGCR8) into a precursor miRNA
(pre-miRNA) (Fig. 1B). This 70-nt long pre-miRNA is exported
to the cytoplasm via Exportin-5 (Fig. 1C) where it will be cleaved
by another nuclease, Dicer, into an imperfect miRNA–miRNA⁄
duplex (Fig. 1D) of 18–25 nucleotides [9]. While the passenger
strand (miRNA⁄, in black in Fig. 1) is commonly degraded, the
mature miRNA guide strand (in red in Fig. 1) is loaded into the
RNA-induced silencing complex (RISC; Fig. 1E) where further reg-
ulations will be undertaken, depending on the level of comple-
mentarity between the miRNA and its target in the 30
untranslated region (30 UTR) of the messenger RNA (mRNA). In
case of perfect complementarity, the mRNA will be cleaved by
RISC and degraded; in case of imperfect complementarity, trans-
lation will be repressed [10]. In mammals, decreased mRNA lev-
els were shown to be preceding protein decrease in 84% cases
[11]. Functional target sites within the mRNA usually consist of
a 6–7-nt long sequence which is complementary to the miRNA
sequence, followed by an adenosine, the so-called miRNA ‘‘seed’’
sequence. Target mRNAs end up in cytoplasmic processing-
bodies (P-bodies) where they are degraded [12]. Interestingly,
other recently discovered classes of non-coding RNAs can also
participate in regulation of gene expression and/or have been
associated with HCC. Ender et al. showed that the small nucleolar
RNA (snoRNA) ACA45 is processed by Dicer into RNAs of miRNA-
like length (20- to 25-nt long) that will bind to Argonaute
proteins (Ago), moreover they demonstrated the miRNA-like
function of ACA45 by luciferase reporter assays [13]. Yang et al.
identiﬁed a long non-coding RNA (lncRNA) named High Expres-
sion in Hepatocellular Carcinoma (lncRNA-HEIH) that is differen-
tially expressed in HCC and whose expression level is positively
associated with tumor recurrence and negatively correlated with
survival. In addition, they showed that shRNA-mediated down-
regulation of lncRNA-HEIH signiﬁcantly inhibited the growth of
tumors in a xenograft mouse model [14].
Regulation of miRNA processing in association with HCC
Mature miRNA processing involves multiple steps, and each can
potentially be affected, having an impact on the resulting net
amount of produced mature miRNA. The process starts with the
pri-miRNA transcription, which can be regulated by transcription
factors or genes that are dysregulated in HCC, and that bind to the
corresponding sequence located upstream in the promoter
region. For example, the oncogenic transcription factor c-Myc
binds upstream of miR-17 and upregulates the transcription of
the miR-17–92 tumor-promoting polycistron [15]. Interestingly,
c-Myc similarly binds upstream of other miRNAs, e.g. let-7 and
miR-26a, this time by repressing their transcription, indicating
that cellular miRNAs can have opposite functions in cancer devel-
opment [16]. In a similar fashion, the tumor-suppressor gene p53
upregulates the transcription of miR-34, resulting in cell cycle1372 Journal of Hepatology 2012arrest and apoptosis [17–20]. Epigenetic mechanisms e.g. histone
deacetylation and DNA methylation can result in miRNA silenc-
ing. For instance, Furuta et al. showed that methylation of miR-
124 and miR-203 genes in HCC cell lines silenced their expression
[21]. The next step of miRNA processing, when Dicer cleaves out
the mature miRNA, can be affected in HCC, e.g. Dicer expression is
altered in many cancers [22]. This results in miRNA dysregulation
and as a consequence, in an abnormal gene expression that may
lead to cancer phenotype. Finally, the stability of the mature miR-
NAmolecule can be affected by differential polyadenylation mod-
iﬁcations. miR-122, a liver-speciﬁc miRNA, is selectively 30
adenylated, which will result in a higher stability in the liver
while it will be destabilized in ﬁbroblasts due to poly(A) poly-
merase GLD-2 depletion [23,24].
Key Points 2
• miRNA polymorphisms have been associated with 
increased risk of developing hepatocellular carcinoma 
(HCC)
• miRNA processing is altered in HCC
• Hepatic miRNAs are dysregulated in HCC and this 
involved in HCC onset and progression
• Cellular miRNAs can be released into the circulation, 
and circulating miRNA levels are also affected in HCC
results in changes in the expression profile of target genesmiRNA polymorphisms
Besides the possible alterations in the miRNA processing, miRNA
polymorphisms can also be associated with an increased risk of
HCC. A miRNA polymorphism consists of a single nucleotide poly-
morphism (SNP) in the miRNA gene. Although rare, a SNP in a
miRNA can affect its transcription, processing, or target recogni-
tion. Since binding of a miRNA to its mRNA target is limited only
to the seed sequence, even one nucleotide change would result in
a different group of genes that would be regulated. Recently, two
groups of investigators have described that a variant of miR-
196a-2 is positively associated with HCC susceptibility, in two
populations of distinctive ethnical background [25,26]. Yet, the
ﬁeld of HCC-associated miRNA polymorphisms and their rele-
vance to disease progression as a result of regulation of different
pools of genes is only starting to develop.
Detection of miRNAs
Since miRNAs are involved in ﬁne-tuning of physiological
responses, they have become of interest for diagnosis and therapy
of a number of diseases; nevertheless, reliable miRNA detection is
a key requirement. Currently, the three most commonly used
detection methods are microarray, RT-qPCR and next-generation
sequencing (NGS). Much less common is the use of Northern blot,
in situ hybridization and bead-based ﬂow cytometry. Microarray
is based on annealing of DNA oligonucleotides to the homologous
sequences, on a microchip. Main advantages are the relatively
low price and the high throughput, but the method has a low






















Fig. 1. miRNA biogenesis. miRNA biogenesis involves multiple steps requiring
(A) RNA Pol II for transcription of the 1–4 kb primary transcript called pri-miRNA,
(B) nuclease Drosha-DGCR8 for cropping of the single-stranded sequences
ﬂanking double-stranded stem–loop structure of the pre-miRNA precursor of
70-nt long, (C) export of the pre-miRNA via Exportin-5 from the nucleus to the
cytoplasm and (D) nuclease Dicer cleavage of the loop to generate the mature
22-nt long miRNA that will be incorporated into the RISC (E). miRNA guide
strand is represented in red, and passenger strand is represented in black.
JOURNAL OF HEPATOLOGY(miRNA families) can hybridize with the same probe. The use of
DNA locked nucleic acid (LNA) oligonucleotides in microarrays
ensures a greater speciﬁcity by increasing the melting tempera-
ture. In addition, the sensitivity has also been increased [27].
miRNA RT-qPCR is based on a stem–loop primer binding to the
mature miRNA during the reverse transcription, making it a
highly speciﬁc technique that can distinguish 1-nt differences
between related miRNAs [28]. Although preampliﬁcation step
sometimes required before the RT-qPCR can induce some bias
and underestimate the concentration of lowly expressed miRNAs,
this method is more sensitive than microarray. Despite its higher
cost, it is currently the method of choice for validation of miRNA
signatures. NGS is a high-throughput technology that provides
global information on all miRNAs in a certain sample. Costs are
much higher and data analysis is more laborious, but NGS pro-
vides quantitative data, allows miRNA discovery and provides
data on miRNA polymorphisms and differential processing.
Finally, the nCounter developed by Nanostring Technologies
(Seattle, WA) is based on annealing of a ﬂuorescent barcode
probe followed by single molecule imaging, without preampliﬁ-
cation step, offering high sensitivity and speciﬁcity. This technol-
ogy offers high-throughput when using up to 800 multiplexed
targets.Journal of Hepatology 2012Key miRNAs dysregulated in HCC
Dysregulation of miRNAs in cancer has been repeatedly
described, e.g. deregulated miRNAs in prostate, bladder, and kid-
ney cancer [29], breast cancer [30], colon cancer [31]. Impor-
tantly, miRNAs are predominantly downregulated in tumor
tissue [32]. Hepatocellular carcinoma is no exception and various
HCC-speciﬁc miRNA signatures have been described (Table 1).
Screens of clinical samples are qualitatively heterogenic, ﬁrstly
because of the variability in the technical procedure, from
method of sampling (surgery or biopsy), time to and procedure
of freezing, RNA isolation, to method of detection. Most miRNA
screens are done using miRNA RT-qPCR, but some publications
report microarray and NGS as described in Table 1. Secondly,
the disease etiology is a signiﬁcant factor of variation. This should
be taken into account when pooling data, as the patient group can
have a single etiology (alcohol or viral) or mixed etiologies (alco-
hol plus viral). Thirdly, the stage of the disease should also be
considered, although miRNA dysregulations occur from an early
stage [33], it is not clear how miRNA expression changes during
disease progression. Finally, the control tissue used for normali-
zation is also of importance, as it can be the healthy liver from
patients with a different pathology or no known pathology, or
non-tumoral liver tissue from the same patient, i.e. with the same
underlying liver disease (e.g. cirrhosis, viral infection), the latter
allowing to look only at intra-individual changes [34]. Neverthe-
less, dysregulation of several key miRNAs appears to be common
to different screens, as described in Table 1.
Use of miRNAs in molecular classiﬁcation of HCC and in prognosis
Key miRNAs are affected in HCC, and different dysregulation pat-
terns can be used to discriminate tumors based on molecular
characteristics. For instance, downregulation of miR-375 has
been associated with b-catenin mutation, and downregulation
of miR-107 with hepatocyte nuclear factor 1a (HNF1a) [35]. Toff-
anin et al. recently proposed a miRNA-based classiﬁcation of HCC
in three subclasses: the wingless-type MMTV integration site,
interferon-related, and proliferation subclasses [36]. Such miR-
NA-based determination of molecular subclasses of HCC could
allow subtype-speciﬁc treatment. miRNA signatures can also be
used to determine disease prognosis, e.g. Budhu et al. identiﬁed
a 20-miRNA signature as a predictor of survival and recurrence
[37]. In addition, low tumoral miR-26 expression has been asso-
ciated with high interleukin-6 (IL6) expression, and shorter sur-
vival [38]; Ji et al. showed a better response of these tumors to
interferon therapy compared to tumors with high miR-26 levels
[38]. It hence appears that miRNA proﬁling may play a crucial
role in the clinic, not only for HCC classiﬁcation and subtype-spe-
ciﬁc treatment allocation, but also for prognosis.Gene targets of miRNAs and their association with HCC
Oncogenic and tumor-suppressive miRNAs
Prior to inhibition of gene expression, mature miRNAs are loaded
into RISC which will mediate recognition of the target mRNAs
and lead to either mRNA degradation or translational repression.
This negative regulation of gene expression by miRNAs leads to avol. 56 j 1371–1383 1373
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balance between miRNA and gene expression level. In the context
of HCC, miRNAs can act either as oncogenes, by inducing progres-
sion of a cell to cancer, or as tumor-suppressors, by preventing
cell progression to cancer miRNAs (Fig. 2, in red) repressing the
expression of oncogenic targets; when downregulated in HCC, a
higher expression of their targets is allowed, hence promoting
the malignant phenotype. Alternatively, upregulation of onco-
genic miRNAs (Fig. 2, in green) in HCC will cause downregulation
of their gene targets, again promoting the malignant phenotype.
Targets of tumor-suppressing miRNAs downregulated in HCC
Being downregulated in HCC, tumor-suppressor miRNAs cause
upregulation of oncogenic target genes, stimulate and/or increase
cellular mechanisms such as cell proliferation, cell cycle regula-
tion, cell migration and invasion, apoptosis, and hence participate
in the establishment and maintenance of the cancer phenotype,
as described in Fig. 2. Cyclin G1 (CCNG1) is one of the most
well-characterized targets of miR-122 [39]. However, miR-122
also targets the anti-apoptotic BCL-W [40] and ADAM17 (a disin-
tegrin and metalloprotease family 17) involved in metastasis
[41]. Additional validated miRNA targets are described in Fig. 2.
Targets of oncogenic miRNAs upregulated in HCC
Oncogenic miRNAs are upregulated in HCC, thus causing down-
regulation of target genes and decrease of cell mechanisms such
as apoptosis, which eventually leads to onset and progression of
the disease, as described in Fig. 2. Overall, less miRNAs are upreg-
ulated than downregulated in cancer [32]. miR-221 targets the
cyclin-dependent kinase inhibitors CDKN1B/p27 [42] and
CDKN1C/p57 [43], which results in an increase in the G1 to S
phase shift and induces cell growth. Another target of miR-221
is the pro-apoptotic BMF of the BCL-2 family [44], therefore in
HCC, BMF downregulation inhibits apoptosis. Enforced miR-221
expression also induces downregulation of DNA damage-induc-
ible transcript 4 (DDIT4), leading to modulation of the mTOR
pathway [45] and of the tumor suppressors thymidylate synthase
(TIMP3) and PTEN [46], which results in enhanced cell migration.Circulating miRNAs
Origin and clinical relevance of circulating miRNAs
Recently it has been described that miRNAs are found in many
body ﬂuids including plasma [47]. Vesicles (microvesicles or exo-
somes) released from cells to the circulation do contain miRNAs
[48]. A positive correlation between cellular and exosomal miR-
NAs levels was reported for a subset of 8 miRNAs, both present-
ing a proﬁle signiﬁcantly different in ovarian cancer compared to
benign ovarian disease [49]. Circulating miRNAs can therefore be
considered representative of some pathological conditions.
Moreover, their accessibility and high stability in the circulation
system [50] make them perfect biomarkers, especially for surveil-
lance of early stage, pre-symptomatic diseases in at-risk patients.
For example, a serum diagnostic test based on a 34-miRNAs
signature, could diagnose early stage lung cancer with 80%
accuracy [51]. This study underscores the remarkable potential
of circulating miRNAs in early, pre-symptomatic disease
diagnosis.1374 Journal of Hepatology 2012Key Points 3
• Circulating plasma miRNA signatures may provide a 
novel diagnosis method for early, pre-symptomatic HCC 
patients, and may prove useful as prognosis biomarkers 
• 
for HCC therapy by potentially affecting several targets 
with only one miRNA; yet more research is required in 
particular concerning possible off-targeting
The field of miRNA-based gene therapy holds promiseCirculating miRNAs associated with HCC
As described above, many miRNAs are dysregulated in HCC.
Therefore, it is anticipated that circulating miRNAs are also
affected during HCC progression. A few studies reported altered
levels of circulating miRNAs in association with HCC (Table 2).
For instance, the serum level of miR-221 was shown to be 4.8-
fold elevated in HCC patients [52]. Additionally, high level of
miR-221 positively correlated with cirrhosis, tumor size and
tumor stage, and negatively correlated with overall survival.
These promising results should be validated in a larger patient
cohort; nevertheless, miR-221 serum level monitoring could be
of clinical relevance as a potential diagnosis tool and biomarker
of treatment efﬁcacy. Indeed, no optimal blood tumor marker
has been developed so far, the performance of a-fetoprotein
(AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3) and des-c-
carboxyprothrombin (DCP) [53] is limited in a surveillance mode
and for early HCC detection. In addition, the American Associa-
tion for the Study of Liver Diseases (AASLD) Practice Guidelines
(July 2010) discarded AFP for surveillance and diagnosis. There-
fore, there is a need for novel markers that would combine the
less invasiveness of a blood test and serve as a reliable early
detection method. miRNAs deﬁnitely have this potential because
not only they can be detected in plasma, but their sensitivity and
stability are suitable for a clinical setting. Depending on the
method, as little as one copy can be detected (see paragraph on
detection). Nevertheless, appropriate controls should be used,
since HCC is most often accompanied by viral infection, cirrhosis,
or other underlying liver conditions. Therefore, in order to assess
the HCC-speciﬁcity of a miRNA, it is critical to ensure not only an
age- and gender-matched control group but they should also be
matched for etiology and severity of underlying liver disease.
For instance, the miRNA proﬁle of three patient groups was com-
pared: 105 patients with HCC (19.1% HBV, 62.9% HCV, 17.1%
other etiology), 107 with chronic liver disease (CLD; 7.5% HBV,
55.1% HCV, 37.4% other etiology) and 71 normal controls [54].
In another study, miR-16 and miR-199a levels were decreased
in serum and signiﬁcantly associated with HCC [54]. miR-16
was more sensitive as HCC detection marker than AFP, DCP,
and AFP-L3. Combination of miR-16 with AFP, DCP, and AFP-L3
allowed detection of 92.4% HCC cases with a high speciﬁcity
(78.5%), and interestingly, it could detect tumors 63 cm with
the same sensitivity (92.4%). This research demonstrates the fea-
sibility of plasma markers for diagnosis of HCC. Circulating miR-
NAs could therefore be used as a ﬁrst-line testing in HCC patients
if they would outperform the currently used tumor markers. The
discovery of circulating miRNAs offers interesting clinical per-
spectives but this ﬁeld of research is quite recent and more work
has to be done. It remains to be established which miRNA canvol. 56 j 1371–1383
Table 1. Key cellular miRNAs dysregulated in HCC (studies based on patient material) compared to the healthy liver (HL).
miRNA Dysregulation
in HCC
Experimental settings HCC etiology miRNA 
detection method
[Ref.]
let-7a Down 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
let-7a Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
let-7a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
let-7b Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
let-7c Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
let-7d Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
let-7e Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
let-7f Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
let-7g Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-9-3p Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-9 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-10a Up 3 HL, 43 HCC HCV RT-qPCR Varnholt et al., 2008 [84]
miR-10b Up 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-15a Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-15a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-16 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-17 Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-17 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-18a Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-18a Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-18b Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-18 Down 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-18 Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-19b Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-20a Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-21 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-21 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-21 Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-21 Up 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-21 Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-22 Down 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-24 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-25 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-25 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-25 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-27a Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-27a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-29c Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-33 Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-34a Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-92 Down 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-92 Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-93 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-93 Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-96 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-99a Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-99a Down 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-100 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-100 Up 3 HL, 43 HCC HCV RT-qPCR Varnholt et al., 2008 [84]
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Experimental settings HCC etiology miRNA 
detection method
[Ref.]
miR-101 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-101 Down 17 paired HL and HCC Mainly HBV Northern blot Su et al., 2009 [83]
miR-101 Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-106b Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-107 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-122a Down 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-122a Up 3 HL, 43 HCC HCV RT-qPCR Varnholt et al., 2008 [84]
miR-122a Down 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-122a Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-122a Down 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-122a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-122 Down 9 paired HL and T1-HCC (stage 1 TNM) 
and 11 paired HL and T3-HCC
 Northern blot Tsai et al., 2009 [41]
miR-124a Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-124a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-124 Down In 11 out of 19 paired HCC and HL NI RT-qPCR Furuta et al., 2009 [21]
miR-125a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-125a Down 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-125a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-125a Down 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-125b Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-125b Down 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-125b Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-126-3p Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-126 Down 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-126 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-127-3p Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-128b Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-129 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-130a Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-130a Down 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-130a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-130b Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-132 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-135a Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-136 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-137 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-139 Down 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-139 Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-141 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-142 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-143 Up 25 paired HL and HCC 12 HBV-, 13 HBV+ RT-qPCR Zhang et al., 2009 [87]
miR-143 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-143 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-145 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-145 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-145 Down 3 HL, 43 HCC HCV RT-qPCR Varnholt et al., 2008 [84]
miR-145 Down 19 paired HL and HCC Mixed etiologies, 
mainly alcohol
RT-qPCR Borel et al., 2011 [34]
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Experimental settings HCC etiology miRNA 
detection method
[Ref.]
miR-145 Down 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-146 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-148a Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-150 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-150 Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-151 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-152 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-155 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-155 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-181a Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-181c Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-182-3p Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-182 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-183 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-185 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-186 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-194 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-195 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-195 Down 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-195 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-195 Up 10 paired HL and HCC HBV-, HCV- Microarray Huang et al., 2008 [79]
miR-195 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-198 Down 3 HL, 43 HCC HCV RT-qPCR Varnholt et al., 2008 [84]
miR-199a-3p Down 19 paired HL and HCC Mixed etiologies, 
mainly alcohol
RT-qPCR Borel et al., 2011 [34]
miR-199a-3p Down 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-199a-3p Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-199a Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-199a Down 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-199a Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-199a Down 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-199a Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-199a Down 19 paired HL and HCC Mixed etiologies, 
mainly alcohol
RT-qPCR Borel et al., 2011 [34]
miR-199a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-199b-3p Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-199b Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-199b Down 19 paired HL and HCC Mixed etiologies, 
mainly alcohol
RT-qPCR Borel et al., 2011 [34]
miR-199b Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-200a Down 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-200a Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-200b Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-200b Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-203 Down 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-205 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-207 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-210 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-210 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
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Experimental settings HCC etiology miRNA 
detection method
[Ref.]
miR-213 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-214 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-214 Down 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-214 Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-215 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-216a Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-216 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-221 Up 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-221 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-221 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-221 Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-221 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-222 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-222 Up 42 paired HL and HCC Mixed etiologies, 
mainly HBV
RT-qPCR Wong et al., 2008 [86]
miR-222 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-222 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-222 Up 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-222 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-223 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-223 Down 42 paired HL and HCC Mixed etiologies, 
mainly HBV
RT-qPCR Wong et al., 2008 [86]
miR-223 Down 21 HL, 17 HCC including 13 pairs Mixed etiologies, 
mainly HCV
Microarray Gramantieri et al., 2007 [39]
miR-223 Down 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-224 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-224 Up 22 HL, 24 HCC including 22 pairs Mixed etiologies Microarray Murakami et al., 2006 [82]
miR-224 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-224 Up 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-224 Up 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-292-3p Down 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-294 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-301 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-301 Up 28 paired HL and HCC Mixed etiologies RT-qPCR Jiang et al., 2008 [80]
miR-324 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-324 Up 19 paired HL and HCC HBV NGS, Northern blot Connolly et al., 2008 [77]
miR-338 Down 20 paired HL and HCC Mixed etiologies Microarray Huang et al., 2009 [78]
miR-362 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-365 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-373 Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-374 Up 19 paired HL and HCC NI RT-qPCR Wang et al., 2008 [85]
miR-376a Up 3 paired HL and HCC NI Microarray Meng et al., 2007 [81]
miR-378 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-382 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-422a Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-422b Down 4 HL, 28 HCC Mixed etiologies RT-qPCR Ladeiro et al., 2008 [35]
miR-424 Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-491 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-500 Up 40 paired HL and HCC Mixed etiologies, 
mainly viral
RT-qPCR Yamamoto et al., 2009 [91]
miR-519 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-520c-3p Down 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
miR-527 Up 3 HL, 5 HCC Mainly HBV Microarray Su et al., 2009 [83]
NI, no information; RT-qPCR, reverse-template quantitative PCR; NGS, next-generation sequencing, HCV, hepatitis C virus; HBV, hepatitis B virus.
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Fig. 2. miRNAs and their oncogenic and tumor-suppressing targets associated
with HCC. Tumor suppressing miRNAs which are downregulated in HCC are
indicated in red and oncogenic miRNAs which are upregulated in HCC are
indicated in green. miRNAs post-transcriptionally repress the expression of genes
involved in cell cycle regulation, (blue); cell proliferation, (grey); apoptosis,
(yellow); cell migration and invasion, (white); and of proto-oncogenes, (purple).
Genes having a positive effect on the cell process are marked in the dark shade,
while genes having a negative effect on the cell process are marked in the light
shade. For example, CCND1 is marked in dark blue, because it causes cell cycle
progression, and has been linked to the development and progression of cancer.
Vice-versa, PTEN is marked in light blue as it causes cell cycle arrest. Additionally,
one gene can be targeted by several miRNAs, for example tumor-suppressor PTEN
was shown to be simultaneously repressed by oncogenic miR-21 and miR-221.
Bar-headed lines indicate post-transcriptional repression of gene expression. Data
presented in this ﬁgure is non-exhaustive and based on literature.
JOURNAL OF HEPATOLOGYsensitively and reliably be correlated with the presence of HCC at
early stages of disease development and prognosis.Cellular miRNAs as therapeutic targets in HCC
Potential of miRNA-based gene therapy
RNAi was identiﬁed in Caenorhabditis elegans in 1998 by Fire and
Mello [55] and in mammalian cells in 2001 by Tuschl [56]. Since
then, RNAi has generated increasing interest and publications in
diverse research areas. The combination of RNAi with the latest
developments in the ﬁeld of gene therapy which rendered it
safer, and the delivery more efﬁcient, opens the door to novel
therapeutic perspectives. Among the many possibilities currently
investigated, the use of cellular miRNAs as therapeutic agents isJournal of Hepatology 2012one of the most promising from a clinical point of view. Many
miRNAs are downregulating genes that are highly relevant to
HCC and therefore contribute to disease progression. Because a
single miRNA could potentially affect several clinically relevant
targets, artiﬁcially increasing or decreasing the expression level
of a given miRNA offers interesting therapeutic perspectives.
Such therapy could even be combined with local chemotherapy
via the transarterial route (transarterial chemoembolization,
TACE) to increase the treatment effectiveness. Nevertheless,
because a miRNA can affect the expression of several down-
stream targets, modulating the expression of a miRNA of interest
could also lead to undesirable off-target effects.
miRNA-based gene therapy for HCC
The main question raised by RNAi-based gene therapy is the
delivery of the effector molecule, which should preferably be con-
trollable, sustained and tissue-speciﬁc. Several groups have cho-
sen for non-viral delivery of synthetic miRNA molecules. miRNA
mimics or miRNA antagomirs can be repeatedly delivered locally
or systemically and that would cause transient suppression of
target gene expression. To prevent rapid degradation of naked
molecules, miRNAs are modiﬁed or conjugated to improve stabil-
ity or target delivery to a speciﬁc tissue. They can be incorporated
into stable nucleic acid lipid particles (SNALPs), a lipid bilayer
coated by polyethylene glycol (PEG) which will protect them
from degradation, prevent immunostimulation and facilitate
their uptake in endosomes [57]. Similarly, 20O-methyl modiﬁca-
tions increase the stability of synthetic molecules, additionally
preventing off-targeting [58]. Mimicking the external viral pro-
tein structure, virus-like particles (VLP) can also be used for syn-
thetic miRNA delivery, yet they are not suitable for all
applications since they stimulate the immune response [59].
However, VLP vehicles take advantage of the natural virus tro-
pism, e.g. HBV in the liver, and can efﬁciently mediate hepatic
gene transfer [60]. Finally, miRNA conjugation to HDL, LDL or
cholesterol will also lead to hepatic uptake [61]. However, even
with the described improvements, miRNAs would need to be
delivered monthly or bimonthly. Landford et al. inhibited miR-
122 expression in 4 chimpanzees using SPC3649 LNA-modiﬁed
oligonucleotides. Because miR-122 stimulates HCV RNA accumu-
lation, miR-122 inhibition leads to an efﬁcient suppression of
HCV replication and stable reduction of viremia in chimpanzees
[62]. A phase I trial for SPC3649 (Miravirsen from Santaris
Pharma) showed that SPC3649 was well-tolerated and the drug
is now in phase II trial. This approach holds promise for HCV
patients and has the advantage that it should not allow the devel-
opment of viral escape variants. Nevertheless Li et al. reported
that mutations in miR-122 binding site in HCV 50 UTR reduced
SPC3649 treatment efﬁcacy [63]. This indicates that viral escape
could still be possible.
Alternatively, gene therapy using virally-delivered miRNAs is
desirable when chronic and genetic diseases need to be treated.
Viral delivery indeed can offer sustained expression after single
dosing, however, in clinical perspective, it raises several ques-
tions concerning safety. Pri-miRNA can be delivered as an expres-
sion cassette using different types of viral vectors. The
advantages and disadvantages of the viral vectors used in gene
therapy clinical trials are summarized in Table 3. Brieﬂy, the main
disadvantage of lentivirus and retrovirus is their integration into
the host genome, which raises safety issues. On the contrary,vol. 56 j 1371–1383 1379
Table 2. Circulating miRNAs candidate biomarkers for HCC.
miRNA Dysregulation 
in plasma
Experimental settings Result [Ref.]
miR-16 Down 71 HL, 105 HCC, 107 CLD
with traditional markers improves diagnostic 
Qu et al., 2011 [54]
miR-21 Up 89 HL, 101 HCC, 48 CH Xu et al., 2010 [90]
miR-21 Up 20 HL, 46 HCC Elevated in HCC Li et al., 2011 [52]
miR-92a Down 10 HL, 10 HCC Decreases post-resection Shigoka et al., 2010 [89]
miR-122 Up 89 HL, 101 HCC, 48 CH Xu et al., 2010 [90]
miR-195 Down 71 HL, 105 HCC, 107 CLD Qu et al., 2011 [54]
miR-199a Down 71 HL, 105 HCC, 107 CLD Qu et al., 2011 [54]
miR-221 Up 20 HL, 46 HCC Elevated in 35/46 HCC, correlates with HCC 
stage and prognosis
Li et al., 2011 [52]
miR-222 Up 20 HL, 46 HCC Elevated in HCC Li et al., 2011 [52]
miR-223 Up 89 HL, 101 HCC, 48 CH Xu et al., 2010 [90]
miR-224 Up 20 HL, 46 HCC Elevated in HCC Li et al., 2011 [52]
miR-500 Up 10 HCC Levels increased in 3/10 HCC, reduced 6 
months post-operation
Yamamoto et al., 2009 [91]
miR-885 Up 10 HL, 15 HCC, 10 LC Marker of liver cirrhosis Gui et al., 2011 [88]
Significant association with HCC, combination
Unspecific marker of liver injury
Unspecific marker of liver injury
Significant association with HCC
Significant association with HCC
Unspecific marker of liver injury
HL, healthy liver; HCC, hepatocellular carcinoma; CH, chronic hepatitis; LC, liver cirrhosis, CLD, chronic liver diseases.
Table 3. Gene therapy vectors used in clinical trials.






Tropism Host genome 
interaction
Immunogenicity
Adenovirus 24.1 7.9 Transient Broad Non-integrating High
Retrovirus 20.8 8 Long lasting Dividing cells only Integrating Low
Vaccinia and 
poxvirus
13.5 250 Transient Broad. Natural tumor tropism Non-integrating High
Adeno-associated 
virus
4.8 4.7 Potential long lasting Broad Non-integrating Low
Herpes simplex 3.3 40 Potential long lasting Broad Non-integrating High
Lentivirus 2.2 8 Long lasting Both dividing and non-dividing cells Integrating Low
Kb, kilobases. (1)Source: gene therapy clinical trials worldwide database, The Journal of Gene Medicine, 2011.
Reviewadeno-associated virus (AAV) genome remains episomal, which
gives it an advantageous safety proﬁle. However, the episomal
presence of AAV questions its relevance for cancer therapy. Up
to now, adenovirus has been widely used in HCC gene therapy
clinical trials [64–70], as well as Vaccinia virus [71]. Despite the
fact that many virus-delivered ‘‘classical’’ gene therapy products
have been developed for HCC and are currently progressing
through clinical trial phases, no virus-delivered miRNA-based
gene therapy has been tested in clinical trials yet. Indeed, more
research still needs to be done to carefully evaluate potential
risks of this approach. Kota et al. showed that self-complemen-
tary AAV serotype 8 (scAAV8)-delivery of miR-26a in tumor-
bearing tet-o-myc; LAP-tTA mice restored miR-26a expression
[72]. Re-expression of miR-26a speciﬁcally reduced cancer cell
proliferation, induced tumor-speciﬁc apoptosis, and suppressed
tumorogenesis. At 3 weeks post-transduction, most liver tissue
in the control group was replaced with tumor while in 8 out of
10 mice of the treated group no or small tumors only were found
[72]. This research demonstrated for the ﬁrst time the therapeu-
tic potential of restoring the expression of a dysregulated miRNA
in the liver. Additional advantages of this approach are that the
miRNA is well-tolerated, given that it is only downregulated in1380 Journal of Hepatology 2012tumor cells, and therefore only tumor cells are affected. However,
its signiﬁcance in patients still needs to be determined.
With the ﬁrst successes of RNA agents in clinical trials, it
becomes clear that miRNAs and their inhibitors hold a great
potential as therapeutics for different cancers including HCC.Conclusions
It is now well-established that miRNAs are key players in many
various biological processes, including development, cellular pro-
liferation, apoptosis, and oncogenesis [3]. In HCC, miRNAs have
aberrant processing and expression proﬁles, in addition, the pro-
ﬁle of circulating miRNAs is also affected, which renders them
potential biomarkers, with possible applications in diagnosis,
especially for early, pre-symptomatic disease, and prognosis of
HCC. One miRNA may target several genes that are involved in
the development and maintenance of the HCC phenotype. There-
fore, miRNA-based gene therapy offers promising perspectives
compared to classical gene therapy for HCC. An additional advan-
tage of miRNAs is that since they encode no protein, they are gen-
erally not immunogenic. However, activation of Toll-likevol. 56 j 1371–1383
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receptors (TLRs), involved in initiation of inﬂammatory responses
to pathogens, can occur, as reviewed by O’Neill et al. [73], indicat-
ing that unanticipated off-target effects can occur in a clinical set-
ting. For instance, the let-7 family regulates the expression of
TLR4 and this can create off-target effects [74]. A positive aspect
of gene therapy for HCC is that the delivery route seems not to be
questioned, up to now direct imaging-guided intratumoral injec-
tion has been the most used strategy in clinical trials, but tumor-
selective intra-arterial administration could be a good alternative
[70]. In HCC, combination of classical and miRNA-based therapies
appears a desirable goal. First, chemo- or radiation therapy can
improve gene transfer efﬁciency and transgene expression
[75,76]. Second, in the case of combined chemo- and gene- ther-
apies, a direct co-injection of both via the intravenous route used
for the TACE procedure, could be suitable, offering a gene therapy
delivery route already clinically approved and in practice. The
discovery of miRNA-mediated gene regulation as a fundamental
post-transcriptional mechanism increases the complexity of can-
cer genetics. However, understanding the molecular mechanisms
by which miRNAs regulate development and tumorogenesis may
lead to novel concepts in the diagnosis and treatment of cancer.
Besides the fact that miRNAs have shown promising results in
pre-clinical studies, miRNA-based gene therapy is not yet suitable
for routine clinical practice.Conﬂict of interest
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